antibody with a challenging ame. This one looks
promising for the treatment of t-cell lymphomas that express the
Mogamulizumab (call it Mogo) targets CCR4 ...
involved in the migration and homing of leukocytes.
ASCO 2013 report:
Randomized phase II study of mogamulizumab (KW-0761)
versus chemo alone for newly diagnosed aggressive adult T-cell
Note that expression of the target was required for eligibility:
Previously untreated patients (pts)
with CCR4-positive ATL
randomly assigned to receive mLSG15 (chemo) plus Moga (arm A)
mLSG15 (chemo) alone (arm B)
Arm A: 52% (Confidence Interval 33, 71)
vs. Arm B: 33% (Confidence Interval 16, 55) and
Arm A: 86% (CI; 63, 96)
vs. Arm B: 75% (CI; 53, 90), respectively.
Note the wide confidence interval - which is due to the small
study size - the best researcher can do because of the low
incidence of the disease.
Technical background on target of mogamulizumab (Mogo):
Targeting Chemokine Receptor CCR4 in Adult T-Cell
Leukemia-Lymphoma and Other T-Cell Lymphomas
Chemokines act as signaling molecules in the migration and
tissue homing of various leukocytes.
Mogamulizumab/KW-0761 is a humanized monoclonal antibody that
recognizes the N-terminal region of human CCR4
CC chemokine receptor 4 (CCR4) is expressed in various types of
PTCL including adult T-cell leukemia-lymphoma (ATL), which has
the worst prognosis among them.
A phase II study of a defucosylated, humanized anti-CCR4
monoclonal antibody, mogamulizumab (KW-0761), yielded an overall
response rate of 50 % (13/26) and a median progression-free
survival of 5.2 months in relapsed patients with CCR4-positive
ATL who had been previously treated with chemotherapy.
Mogamulizumab also showed potential efficacy for cutaneous
T-cell lymphoma in a US phase I/II study. Further preclinical
and clinical investigations are needed to examine whether
concomitant use of this novel agent with other agents with
different mechanisms of action would be more effective for ATL
and other PTCLs.
To find trials for this agent,